Zilberberg MD, et al. - Analysis of the Health Care Utilization Project’s data from the Agency for Healthcare Research and Quality for 2009–2013 was performed to determine the morbidity and mortality burden associated with invasive aspergillosis (IA) in the United States. Researchers performed a comparison of characteristics and outcomes between those with (IA) and without IA (non-IA). Observations suggest that IA is rarely encountered even among high-risk groups. However, when present, IA is associated with increased hospital mortality and 30-day readmission rates, excess duration of hospitalization, and costs. The aggregate IA-attributable excess costs may reach $600 million annually given nearly 40000 annual admissions for IA in the United States.